Cleo Diagnostics (ASX:COV) Debt-to-Equity: 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:COV Cleo Diagnostics Ltd ASX:COV
36 GF Score
Price A$0.35
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Debt-to-Equity?

Cleo Diagnostics ASX:COV +1.47% 36 Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus rates ASX:COV with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 697 Medical Devices & Instruments companies, Cleo Diagnostics ranks worse than 143471.88% on this metric.

Cleo Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was A$0.00 Mil. Cleo Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was A$0.00 Mil. Cleo Diagnostics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was A$5.01 Mil. Cleo Diagnostics's debt to equity for the quarter that ended in Jun. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cleo Diagnostics's Debt-to-Equity or its related term are showing as below:

During the past 4 years, the highest Debt-to-Equity Ratio of Cleo Diagnostics was -1.70. The lowest was -1.70. And the median was -1.70.

ASX:COV's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.23
* Ranked among companies with meaningful Debt-to-Equity only.

Cleo Diagnostics  (ASX:COV) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cleo Diagnostics Debt-to-Equity Related Terms

Cleo Diagnostics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Debt-to-Equity Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25 Jun26
Debt-to-Equity
-1.70 0.00 0.00 0.00

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-Equity Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

ASX:COV vs ABT, SYK, MDT: Debt-to-Equity Comparison

For the Medical Devices subindustry, Cleo Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Debt-to-Equity falls into.


ASX:COV
36GF Score
Cleo Diagnostics Ltd ASX:COV
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cleo Diagnostics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 5.01
=0.00

Cleo Diagnostics's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 5.01
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Cleo Diagnostics (ASX:COV) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cleo Diagnostics and its competitors. According to the industry distribution chart, Cleo Diagnostics ranks #999999 out of 697 companies in the Medical Devices & Instruments industry.
Is Cleo Diagnostics' Debt-to-Equity too high?
Cleo Diagnostics' current Debt-to-Equity is 0.00. Based on the distribution chart, Cleo Diagnostics ranks #999999 out of 697 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cleo Diagnostics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cleo Diagnostics ranks #999999 out of 697 companies for Debt-to-Equity. This places Cleo Diagnostics in the lower half of its industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cleo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleo Diagnostics's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Cleo Diagnostics' overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
36GF Score

Get the complete analysis for ASX:COV

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.35
Price